Capricor Therapeutics (NASDAQ:CAPR) Trading Up 11% – Still a Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price was up 11% during mid-day trading on Thursday . The stock traded as high as $9.73 and last traded at $9.4990. 1,539,920 shares traded hands during mid-day trading, a decline of 49% from the average session volume of 3,049,009 shares. The stock had previously closed at $8.56.

Trending Headlines about Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Capricor will present 24-month HOPE-3 and open-label-extension data at the World Muscle Society Congress from September 29 to October 3. The presentations will include delayed-start and natural-history analyses submitted with a major amendment to the deramiocel biologics license application (BLA), providing a near-term opportunity for additional clinical visibility. The FDA’s target action date is November 22, 2026. Capricor to present HOPE-3 data at WMS 2026
• Neutral Sentiment: Brokerage coverage cited in recent reports assigns Capricor a consensus “Hold” rating, suggesting analysts are waiting for clearer regulatory and clinical developments before taking a more constructive view.
• Negative Sentiment: The FDA has extended its review of Capricor’s deramiocel BLA, increasing uncertainty over the timing and outcome of potential approval. The extension follows a major submission amendment and has intensified scrutiny of the application. FDA review extension and class-action deadline
• Negative Sentiment: Several law firms are promoting an ongoing securities class action covering investors who purchased CAPR shares primarily between December 17, 2025 and July 26, 2026. The complaints allege, among other issues, that Capricor’s Phase 3 HOPE-3 trial did not follow specified blinding and protocol procedures and that the final protocol differed from the statistical analysis plan. September 28, 2026 is the lead-plaintiff deadline. The announcements are allegations, not findings of liability, but they add litigation and reputational risk. Capricor class-action deadline alert

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on CAPR shares. Piper Sandler raised Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Tuesday, September 1st. B Riley raised shares of Capricor Therapeutics from a “neutral” rating to a “buy” rating in a research report on Monday. LADENBURG THALM/SH SH cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, July 30th. Oppenheimer reaffirmed an “outperform” rating on shares of Capricor Therapeutics in a research report on Thursday. Finally, JonesTrading lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 31st. Five equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $30.25.

Capricor Therapeutics Stock Down 3.7%

The business has a 50-day moving average of $9.72 and a 200-day moving average of $22.54. The stock has a market cap of $527.33 million, a price-to-earnings ratio of -3.70 and a beta of 0.72.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Equities analysts anticipate that Capricor Therapeutics, Inc. will post -1.71 earnings per share for the current year.

Insider Activity at Capricor Therapeutics

In related news, CFO Anthony Bergmann sold 24,100 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares in the company, valued at approximately $340,954.74. This represents a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last three months, insiders sold 25,000 shares of company stock valued at $759,158. Insiders own 9.20% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC increased its stake in shares of Capricor Therapeutics by 57.8% during the 2nd quarter. Squarepoint Ops LLC now owns 19,731 shares of the biotechnology company’s stock worth $475,000 after purchasing an additional 7,231 shares during the last quarter. Montanova Capital LLC lifted its stake in shares of Capricor Therapeutics by 7.2% in the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock valued at $98,554,000 after purchasing an additional 274,184 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Capricor Therapeutics in the 2nd quarter valued at $3,895,000. Glenmede Trust Co. NA lifted its stake in shares of Capricor Therapeutics by 13.2% in the 1st quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company’s stock valued at $1,104,000 after purchasing an additional 4,240 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Capricor Therapeutics by 672.0% in the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock worth $12,631,000 after purchasing an additional 361,664 shares in the last quarter. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell- and exosome-based therapies for serious diseases. The company’s programs are designed to use regenerative medicine and targeted delivery technologies to address conditions with limited treatment options.

Its leading therapeutic candidate is deramiocel, also known as CAP-1002, an allogeneic cell therapy derived from cardiosphere-derived cells. The program has been studied primarily for Duchenne muscular dystrophy, a genetic disorder that causes progressive muscle weakness and cardiac complications.